β-Asarone Alleviates High-Glucose-Induced Oxidative Damage via Inhibition of ROS Generation and Inactivation of the

Cheol Park1, Hee-Jae Cha2, Hyun Hwangbo3

  • 1Department Division of Basic Sciences, College of Liberal Studies, Dong-eui University, Busan 47340, Republic of Korea.

Insights

Beta-asarone protects retinal pigment epithelial cells from high glucose-induced damage by reducing oxidative stress and inhibiting inflammatory pathways. This natural compound shows potential for treating diabetic retinopathy (DR).

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss, linked to hyperglycemia-induced oxidative stress.
  • Reactive oxygen species (ROS) play a critical role in DR pathogenesis.
  • The therapeutic potential of beta-asarone, an antioxidant from Acori graminei Rhizoma, for DR is unexplored.

Purpose of the Study:

  • To investigate the protective effects of beta-asarone against high-glucose (HG)-induced oxidative damage in human retinal pigment epithelial (RPE) cells.
  • To elucidate the underlying mechanisms, including ROS scavenging and modulation of inflammatory pathways.

Main Methods:

  • ARPE-19 cells were treated with high glucose (HG) with or without beta-asarone.
  • Assessed cytotoxicity, apoptosis, DNA damage, and ROS generation.
  • Measured lactate dehydrogenase, manganese superoxide dismutase, and glutathione levels.
  • Analyzed the expression and activation of inflammatory markers, including IL-1β, IL-18, NF-κB, and NLRP3 inflammasome components.

Main Results:

  • Beta-asarone significantly reduced HG-induced cytotoxicity, apoptosis, and DNA damage in RPE cells.
  • It effectively scavenged ROS, attenuated lactate dehydrogenase release, and enhanced antioxidant enzyme activities.
  • Beta-asarone suppressed the release and activation of IL-1β, IL-18, NF-κB, and NLRP3 inflammasome components.

Conclusions:

  • Beta-asarone protects RPE cells from HG-induced injury by inhibiting ROS generation and NF-κB/NLRP3 inflammasome activation.
  • These findings suggest beta-asarone holds promise as a potential therapeutic agent for diabetic retinopathy.